Table of Contents Author Guidelines Submit a Manuscript
International Journal of Inflammation
Volume 2012, Article ID 412178, 11 pages
Research Article

Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease

1Department of Immunopharmacology, Novo Nordisk A/S, 2760 Måløv, Denmark
2Department of Medical Anatomy, The Panum Institute, University of Copenhagen, 2200 Copenhagen, Denmark
3Department of Haemophilia Biology, Novo Nordisk A/S, 2760 Måløv, Denmark

Received 13 September 2011; Revised 21 October 2011; Accepted 5 November 2011

Academic Editor: Christoph Gasche

Copyright © 2012 Thomas Lindebo Holm et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Animal models are important tools in the development of new drug candidates against the inflammatory bowel diseases (IBDs) Crohn's disease and ulcerative colitis. In order to increase the translational value of these models, it is important to increase knowledge relating to standard drugs. Using the SCID adoptive transfer colitis model, we have evaluated the effect of currently used IBD drugs and IBD drug candidates, that is, anti-TNF-α, TNFR-Fc, anti-IL-12p40, anti-IL-6, CTLA4-Ig, anti-α4β7 integrin, enrofloxacin/metronidazole, and cyclosporine. We found that anti-TNF-α, antibiotics, anti-IL-12p40, anti-α4β7 integrin, CTLA4-Ig, and anti-IL-6 effectively prevented onset of colitis, whereas TNFR-Fc and cyclosporine did not. In intervention studies, antibiotics, anti-IL-12p40, and CTLA4-Ig induced remission, whereas the other compounds did not. The data suggest that the adoptive transfer model and the inflammatory bowel diseases have some main inflammatory pathways in common. The finding that some well-established IBD therapeutics do not have any effect in the model highlights important differences between the experimental model and the human disease.